Company 11, Second Military Medical University, Shanghai, People's Republic of China.
Am J Cardiovasc Drugs. 2012 Oct 1;12(5):335-44. doi: 10.1007/BF03261842.
Angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been shown to be effective and well tolerated in hypertensive patients. Olmesartan is the seventh angiotensin receptor blocker licensed by the US Food and Drug Administration. The aim of this meta-analysis was to determine the efficacy and tolerability of olmesartan medoxomil in comparison with other ARBs.
Reports of randomized controlled trials (RCTs) of olmesartan versus other ARBs were identified through a systematic search of PubMed (up to July 2010), EMBASE (1980 to July 2010), SinoMed (up to July 2010), and the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 7, 2010).
Pertinent studies were selected through extensive searches of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and SinoMed. Two of the authors abstracted data from the identified studies independently. Criteria for inclusion in our meta-analyses were randomized clinical trials in which patients were receiving an ARB and outcome data for blood pressure reduction or the incidence of adverse events were available. Quantitative and qualitative analyses of data from all RCTs meeting the criteria were performed. Our meta-analysis was undertaken according to the Quality of Reporting Meta-analyses (QUOROM) statement.
Twenty-two studies with data from 4892 patients were considered for analyses. Olmesartan provided greater diastolic blood pressure (DBP) and systolic blood pressure (SBP) reductions compared with losartan (DBP: 95% confidence interval [CI] 0.59, 2.62; SBP: 95% CI 0.46, 5.92). Olmesartan provided greater SBP reductions compared with valsartan (95% CI 0.29, 3.16). Similar blood pressure response rates and incidence of adverse events were found with losartan, valsartan, candesartan, and irbesartan.
Olmesartan provides better antihypertensive efficacy than losartan and valsartan and has no association with an increased risk of adverse events in comparison with losartan, valsartan, candesartan, and irbesartan.
血管紧张素Ⅱ 1 型受体拮抗剂（血管紧张素受体阻滞剂[ARB]）已被证明在高血压患者中有效且耐受性良好。奥美沙坦是美国食品和药物管理局批准的第七种血管紧张素受体阻滞剂。本荟萃分析的目的是确定奥美沙坦与其他 ARB 相比的疗效和耐受性。
通过系统搜索 PubMed（截至 2010 年 7 月）、EMBASE（1980 年至 2010 年 7 月）、SinoMed（截至 2010 年 7 月）和 Cochrane 对照试验中心注册库（Cochrane 图书馆 2010 年第 7 期），确定了奥美沙坦与其他 ARB 比较的随机对照试验（RCT）报告。
通过对 PubMed、EMBASE、Cochrane 对照试验中心注册库和 SinoMed 的广泛搜索，选择了相关研究。两位作者独立从确定的研究中提取数据。纳入我们荟萃分析的标准是接受 ARB 治疗的患者的随机临床试验，并且可获得血压降低或不良事件发生率的数据。对符合标准的所有 RCT 的数据进行了定量和定性分析。我们的荟萃分析是根据报告荟萃分析质量（QUOROM）声明进行的。
考虑进行分析的有 22 项研究，共有 4892 名患者的数据。与氯沙坦相比，奥美沙坦可更大程度地降低舒张压（DBP）和收缩压（SBP）（DBP：95%置信区间[CI]0.59，2.62；SBP：95% CI 0.46，5.92）。与缬沙坦相比，奥美沙坦可更大程度地降低收缩压（95% CI 0.29，3.16）。氯沙坦、缬沙坦、坎地沙坦和厄贝沙坦的血压反应率和不良事件发生率相似。
与氯沙坦和缬沙坦相比，奥美沙坦提供更好的降压疗效，与氯沙坦、缬沙坦、坎地沙坦和厄贝沙坦相比，不会增加不良事件的风险。
